The Sage Group

THE SAGE GROUP Reports that in 2010 Approximately 2.8 Million People in the United States Suffered from Critical Limb Ischemia.

ATLANTA, December 14, 2010 (BUSINESS WIRE)—According to a recent analysis published by THE SAGE GROUP, almost 18 million U.S. citizens suffer from peripheral artery disease (PAD). Reflecting the aging population this number is projected to increase to 24 million by 2030.

Critical limb ischemia (CLI), the most severe and deadly form of the disease, currently afflicts 2.8 to 3.5 million of those with PAD. By 2030 the U.S. prevalence of CLI is forecast to grow to between 4.5 and 5.6 million.

“The societal costs and economic consequences of almost 3 million people with critical limb ischemia are profound,” declared Mary L. Yost, President of THE SAGE GROUP.

According to data presented at the June 2010, New Cardiovascular Horizons (NCVH) meeting, CLI hospital treatment costs exceed $10 billion.

“CLI is an expensive cardiovascular disease to treat. Average inpatient charges for CLI are $55,000—twice as high as those for stroke and almost $1,000 more than for heart attack,” Yost stated. “CLI is also an extremely fatal disease. The 70% five-year all-cause mortality rate far exceeds the 21% and 28% rates for coronary artery disease and stroke respectively,” continued Ms. Yost.

Critical limb ischemia patients represent a significant market opportunity for endovascular and surgical products, as well as for pharmaceutical risk-factor modification therapies.

According to Ms. Yost, “Even though only 15%-20% of these patients are currently revascularized, the endovascular market exceeds $565 million. However, if all patients are diagnosed and treated appropriately the endovascular market represents $3.3 billion. Proven risk-factor modification therapies are also underutilized. Risk factor treatment in currently untreated patients represents an additional $2.5 billion in antihypertensive, antilipid and antiplatelet revenues.”

“No option patients, or those who cannot be revascularized, represent an extremely large market,” Ms. Yost stated. “According to our research, between 1.1 and 2.0 million CLI patients are currently ineligible for revascularization. These patients might be candidates for stem cell therapies or other new biotechnology products,” she continued.

About the Report: Critical Limb Ischemia Volume I United States Epidemiology, 2010

The 2010 revised report presents new, higher estimates for peripheral artery disease and critical limb ischemia based on the increased 2005-2006 NHANES prevalence of diabetes.

CLI Volume I contains a comprehensive analysis of: the two most common comorbidities, diabetes and chronic kidney disease; the prevalence of critical limb ischemia in the United States; CLI projections for the 2010-2030 period; the market implications for endovascular and pharmaceutical therapies and the most appropriate methods for estimating the prevalence of CLI.

Additional information:


THE SAGE GROUP, a research and consulting company, specializes in atherosclerotic disease in the lower limbs, specifically PAD (Peripheral Artery Disease), CLI (Critical Limb Ischemia) and ALI (Acute Limb Ischemia). The most recent research focuses on PAD and diabetic foot ulcers (DFU).

For additional information visit


Mary Yost, 404-520-6652